Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s December 19, 2023 Read More »
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 December 13, 2023 Read More »
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives November 21, 2023 Read More »
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy October 19, 2023 Read More »
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials August 14, 2023 Read More »
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico August 2, 2023 Read More »
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference July 18, 2023 Read More »
